International Nonproprietary Names
for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in the WHO Chronicle.

The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

**PROPOSED INTERNATIONAL NONPROPRIETARY NAMES (Prop. I.N.N.): LIST 22**

<table>
<thead>
<tr>
<th>Proposed International Nonproprietary Name (Latin, English)</th>
<th>Chemical Name or Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>acedepsonum acedapson</td>
<td>4',4''-sulfonylbis(acetanilide)</td>
</tr>
<tr>
<td></td>
<td>C_{12}H_{12}N_2O_6S</td>
</tr>
<tr>
<td></td>
<td><img src="image1" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>acequinolinum acequinoline</td>
<td>7-methoxy-2,4-dimethyl-3-quinolyl methyl ketone</td>
</tr>
<tr>
<td></td>
<td>C_{13}H_{14}NO_3</td>
</tr>
<tr>
<td></td>
<td><img src="image2" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>acidum bensulodazicum bensulodac acid</td>
<td>5-benzylidihydro-6-thioxo-2H-1,3,5-thiadiazine-3(4H)-acetic acid</td>
</tr>
<tr>
<td></td>
<td>C_{10}H_{9}N_O_5S</td>
</tr>
<tr>
<td></td>
<td><img src="image3" alt="Chemical Structure" /></td>
</tr>
</tbody>
</table>

*See Annex, p. 30.

---


acidum etidronicum
etidronic acid

(1-hydroxyethylidene)diphosphonic acid
C₉H₄O₇P₂

acidum fenamicum
fenamic acid

1-(diethylcarbamoyl)-1,2,3,4,5,5,7,8-octahydro-6,6-dimethyl-8-oxo-3-phenyl-2-naphthoic acid
C₇H₆N₂O₫

acidum fenozicicum
fenozic acid

2-(o-chlorophenyl)-4-thiazolesuccinic acid
C₈H₇CINO₃S

acidum flavodicum
flavodinic acid

[4-oxo-2-phenyl-4H-1-benzopyran-5,7-diyldioxy]diacetic acid
C₉H₈O₄
acidum hopantemicum
hopantetic acid

\[ \text{O-}(\pm)-4-(\text{4,4-dihydroxy-3,3-dimethyl} \text{butyramido}) \text{butyric acid} \]
\[ \text{C}_{10}\text{H}_{16}\text{O}_{5} \]

\[ \text{HOCH}_2-\text{C}-\text{CHOH}-\text{CD}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOH} \]
\[ \text{CH}_3 \]

acidum ioearcicum
ioearcic acid

\[ 5,5'-\text{di(ethylimino)}\text{bis}[2,4,6\text{-triiodo-}N\text{-methylisophthalamic acid}] \]
\[ \text{C}_{22}\text{H}_{18}\text{I}_6\text{N}_4\text{O}_6 \]

acidum iozirizicum
iozirizic acid

\[ 2,4,6\text{-triiodo-3-} \{\text{2-[2-[2-}(\text{methoxyethoxy})\text{ethoxy}]ethoxy}\text{acetamido}\} \text{benzoic acid} \]
\[ \text{C}_{26}\text{H}_{19}\text{I}_6\text{N}_4\text{O}_6 \]

acidum ioxtalamicum
ioxtalic acid

\[ 5\text{-acetamido-}N\text{-}(\text{2-hydroxyethyl})\text{-2,4,6-triiodoisophthalamic acid} \]
\[ \text{C}_{31}\text{H}_{21}\text{I}_6\text{N}_4\text{O}_6 \]

acidum oxiniacicum
oxiniacic acid

\[ \text{nicotinic acid 1-oxide} \]
\[ \text{C}_{7}\text{H}_{11}\text{N}_2\text{O}_2 \]
<table>
<thead>
<tr>
<th><strong>Proposed International Nonproprietary Name</strong></th>
<th><strong>Chemical Name or Description, Molecular and Graphic Formule</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>acronium</td>
<td>3,12-dihydro-6-methoxy-3,12-trimethyl-7H-pyano[2,3-c]acridin-7-one</td>
</tr>
<tr>
<td>acronine</td>
<td>C_{18}H_{1}<em>{9}NO</em>{5}</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Acronium Structure" /></td>
</tr>
<tr>
<td>alufibratum</td>
<td>bis[3-(p-chlorophenoxy)-2-methylpropionate]hydroxyaluminum</td>
</tr>
<tr>
<td>alufibrate</td>
<td>CaH_{14}AlCl_{10}O_{9}</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Alufibratum Structure" /></td>
</tr>
<tr>
<td>aminoguinalum</td>
<td>7-chloro-2-(o-chlorostyryl)-4-[(4-(diethylamino)-1-methylbutyl)amino]quinoline</td>
</tr>
<tr>
<td>aminquinol</td>
<td>C_{25}H_{30}ClN_{5}</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Aminoguinalum Structure" /></td>
</tr>
<tr>
<td>amoproxan</td>
<td>α-(isopentyloxymethyl)-4-morpholineethanol 3,4,5-trimethoxybenzoate (ester)</td>
</tr>
<tr>
<td>amoxaean</td>
<td>C_{26}H_{26}NO_{5}</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Amoproxan Structure" /></td>
</tr>
</tbody>
</table>
bendazocum
bendazac

{(1-benzyl-1H-indazol-3-yl)ox}acetic acid
C_{10}H_{11}N_{2}O_{3}

\[
\begin{array}{c}
\text{CH}_{2} \\
\text{N} \\
\text{O} - \text{CH}_{2} - \text{COOH}
\end{array}
\]

benoxafosum
benoxafos

5-[(5,7-dichlorobenzoxazol-2-yl)methyl]-O,O-diethyl phosphoro-
dithioate
C_{11}H_{8}Cl_{3}NO_{3}PS_{2}

\[
\begin{array}{c}
\text{Cl} \\
\text{O} - \text{CH}_{2} - \text{S} - \text{P} \quad \text{O}_{2} \text{C}_{2} \text{H}_{5} \\
\text{Cl}
\end{array}
\]

brinasum
brinase

fibrinolytic enzyme derived from Aspergillus oryzae

bromazepamum
bromazepam

7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one
C_{16}H_{12}BrN_{2}O

\[
\begin{array}{c}
\text{Br} \\
\text{N} \\
\text{N}
\end{array}
\]

bucrilatum
bucrilate

isobutyl 2-cyanoacrylate
C_{6}H_{15}NO_{2}

\[
\begin{array}{c}
\text{CN} \\
\text{CH}_{3} \\
\text{H}_{2} \text{C} = \text{C} - \text{O} - \text{CH}_{2} - \text{CH} - \text{CH}_{3}
\end{array}
\]
Proposed International Nonproprietary Name
(Latin, English)

*Proposed International Nonproprietary Name*
*Chemical Name or Description, Molecular and Graphic Formulas*

bunolofom
bunolof

\((\pm)-5-\{(\text{tert}-\text{butylamino})-2\text{-hydroxypropoxy}\}-3,4\text{-dihydro-1}(2H)\text{-}
\text{naphthalenone}\)

\(\text{C}_{11}\text{H}_{13}\text{NO}_3\)

\[
\begin{array}{c}
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\end{array}
\]

butamiratum
butamirate

\(2\{(\text{diethylamino})\text{ethoxy}\}\text{ethyl 2-phenylbutyrate}\)

\(\text{C}_{16}\text{H}_{24}\text{NO}_3\)

\[
\begin{array}{c}
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\end{array}
\]

chromocarbum
chromocarb

\(4\text{-oxo-4H-1-benzopyran-2-carboxylic acid}\)

\(\text{C}_{16}\text{H}_{18}\text{O}_3\)

\[
\begin{array}{c}
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\end{array}
\]

cacidacillinum
cacidacillin

\(6\{(1\text{-aminocyclohexanecarboxamido})-3,3\text{-dimethyl-7-oxo-4-thia-}
1\text{-azabicyclo[3.2.0]heptane-2-carboxylic acid}\)

\(\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_5\)

\[
\begin{array}{c}
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\end{array}
\]

cinoxatatum
cinoxate

\(2\text{-ethoxyethyl }\rho\text{-methoxycinnamate}\)

\(\text{C}_{16}\text{H}_{18}\text{O}_5\)

\[
\begin{array}{c}
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\text{O} \\
\end{array}
\]
Proposed International Nonproprietary Name (Latin, English)

ciproquinatum
ciproquine

Chemical Name or Description, Molecular and Graphic Formulas

ethyl 8,7-bis(cyclopropymethoxy)-4-hydroxy-3-quinolincarboxylate

\[\text{C}_9\text{H}_7\text{NO}_3\]

\[
\begin{array}{c}
\text{CH}_2\text{O} \\
\text{CH}_2\text{O} \\
\text{OH} \\
\text{CO} \to \text{C}_2\text{H}_5
\end{array}
\]

clonazepamum
clonazepam

5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one

\[\text{C}_{14}\text{H}_9\text{ClN}_3\text{O}_3\]

\[
\begin{array}{c}
\text{O}_2\text{N} \\
\text{H} \\
\text{N} \\
\text{Cl}
\end{array}
\]

clonixerilum
clonixeril

2,3-dihydroxypropyl 2-(3-chloro-o-toluidino)nicotinate

\[\text{C}_{19}\text{H}_{16}\text{ClN}_2\text{O}_4\]

\[
\begin{array}{c}
\text{H}_3\text{C} \\
\text{Cl}
\end{array}
\begin{array}{c}
\text{N} \\
\text{N} \\
\text{CO} \to \text{CH}_2 \to \text{CHOH} \to \text{CH}_2\text{OH}
\end{array}
\]

clonixinum
clonixin

2-(3-chloro-o-toluidino)nicotin acid

\[\text{C}_{14}\text{H}_7\text{ClN}_2\text{O}_2\]

\[
\begin{array}{c}
\text{H}_3\text{C} \\
\text{Cl}
\end{array}
\begin{array}{c}
\text{N} \\
\text{N} \\
\text{COOH}
\end{array}
\]
**Proposed International Nonproprietary Name (Latin, English)**

**Chemical Name or Description, Molecular and Graphic Formulas**

**Clorterumine**
- **Clorterumine**
- $\text{o-chloro-\text{a},\text{o}-\text{dimethyl}phenethylamine}$
  - $\text{C}_9\text{H}_9\text{ClN}$
  - ![Chemical Structure](image)

**Cloriramidine**
- **Cloriramidine**
- $\text{8-chloro-11-\{3-(dimethylamino)ethyl\}-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine}$
  - $\text{C}_{23}\text{H}_{20}\text{ClN}_2$
  - ![Chemical Structure](image)

**Clostebolum**
- **Clostebol**
- $\text{4-chloro-17\beta-hydroxyandrost-4-en-3-one}$
  - $\text{C}_{20}\text{H}_{30}\text{ClO}_3$
  - ![Chemical Structure](image)

**Clorazapinum**
- **Clorazapine**
- $\text{8-chloro-11-\{4-methyl-1-piperazinyl\}-5H-dibenzo[\text{a,e}][1,4]diazepine}$
  - $\text{C}_{21}\text{H}_{21}\text{ClN}_3$
  - ![Chemical Structure](image)
cofisatinum
cofisatin

3,3-bis(p-hydroxyphenyl)-2-indolinone 3,7,12-trioxo-5β-cholan-24-oic acid diester
C₂₀H₂₀NO₁₂

colestipol
colestatin

tetraethylene pentamine polymer with 1-chloro-2,3-epoxypropane

1-(3-mercaptopropionic acid)-oxytocin
C₉H₁₆N₂O₃S₁
proprietary Name
(Latin, English) Chemical Name or Description, Molecular and Graphic Formulas

**dextromethorphan**
dextromethorphan

(+)-2-(1-benzyl-4-piperidyl)-2-phenylglycine
C₂₀H₁₇N₂O₂

**diamocaine**
diamocaine

1-(2-anilinomethyl)-4-[8-(diethylamino)ethoxy]-4-phenylpiperidine
C₂₀H₂₂N₂O

**difenphenic**
difenphenic

4-[2-(diethylamino)ethoxy]phenyl phenethyl ketone
C₂₃H₂₈N₂O₂

**diazepam**
diazepam

tetrahydro-1H-1,4-diazepine-1,4(5H)-dipropeno 3,4,5-trimethoxybenzoate (ester)
C₃₄H₄₂N₂O₈

**dipropylamine**
dipropylamine

3-(2,3-dihydroxypropyl)-2-methyl-4(3H)-quinazolinone
C₂₃H₂₃N₂O₅
<table>
<thead>
<tr>
<th>Proposed International Nonproprietary Name</th>
<th>Chemical Name or Description, Molecular and Graphic Formulae</th>
</tr>
</thead>
<tbody>
<tr>
<td>ecinaminum ecnmine</td>
<td>2-(diphenylmethylene)butylamine</td>
</tr>
<tr>
<td></td>
<td>[\text{C}_4\text{H}_4\text{N}]</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>edogestronum edogestrone</td>
<td>17-hydroxy-6-methylpregn-5-ene-3,20-dione cyclic 3-(ethylene acetal) acetate</td>
</tr>
<tr>
<td></td>
<td>[\text{C}<em>{19}\text{H}</em>{24}\text{O}_7]</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>enestebolium enestebol</td>
<td>4,17β-dihydroxy-17-methylandrosta-1,4-dien-3-one</td>
</tr>
<tr>
<td></td>
<td>[\text{C}<em>{20}\text{H}</em>{24}\text{O}_7]</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>epimestrolium esimestrol</td>
<td>3-methoxyestra-1,3,5(10)-triene-16α,17β-diol</td>
</tr>
<tr>
<td></td>
<td>[\text{C}<em>{19}\text{H}</em>{24}\text{O}_7]</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
</tbody>
</table>
Proposed International Nonproprietary Name

- etopridol
- etopridol

Chemical Name or Description, Molecular and Graphic Formulae

- 4-(β-methoxyphenethyl)-α-phenyl-1-piperazinopropanol
  \[\text{C}_{15}\text{H}_{21}\text{N}_2\text{O}_3\]

- 8-[[bis(2-hydroxyethyl)amino]methyl]-6,7-dihydroxy-4-methyl-coumarin
  \[\text{C}_{15}\text{H}_{16}\text{NO}_5\]

- 1-(2-hydroxyethyl)-1-methylpyrroldinium iodide benzoate (ester)
  \[\text{C}_{13}\text{H}_{18}\text{INO}_4\]

- 1-[2-(dimethylamino)ethyl]indol-3-yl ethyl ketone oxime
  \[\text{C}_{17}\text{H}_{21}\text{NO}_2\]
Proposed International Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formula

**euprocium**
**euprocin**

\[ \text{O'isopentylhydrocurepine} \]
\[ C_{14}H_{25}N_3O_2 \]

![euprocium chemical structure]

**flucloprone acetonide**
**flucloprone acetonide**

\[ 9,11\beta\text{-dichloro-6u-fluoro-16a,17,21-trihydroxyprogesta-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone} \]
\[ C_{25}H_{32}Cl_{10}O_{10} \]

![flucloprone acetonide chemical structure]

**flucytosinum**
**flucytosine**

\[ 5\text{-fluorocytosine} \]
\[ C_{7}H_{13}FN_{3}O \]

![flucytosine chemical structure]

**flu fenisalum**
**flu fenisal**

\[ 4\text{-fluoro-4-hydroxy-3-biphenylcarboxylic acid acetate} \]
\[ C_{22}H_{13}FO \]

![flu fenisal chemical structure]
flunarizinum
flunarizine

1-cinnamyl-4-[bis(2-fluorophenyl)methyl]piperazine
C_{19}H_{18}F_{6}N_{2}

\[
\begin{align*}
\text{CH}_2-\text{CH}=\text{CH}- & \\
& \text{N} \\
& \text{N} \\
& \text{CH} \\
& \text{F} \\
& \text{F}
\end{align*}
\]

flutiazinum
flutazin

8-(trifluoromethyl)phenothiazine-1-carboxylic acid
C_{14}H_{13}F_{3}N_{2}O_{4}S

\[
\text{F}_3\text{C} \quad \text{H} \quad \text{N} \quad \text{COOH}
\]

ftorinazinum
ftorinazine

10-[3-(4-methyl-1-piperazinyl)propionyl]-2-(trifluoromethyl)phenothiazine
C_{19}H_{19}F_{3}N_{2}O_{4}S

\[
\text{CO} - \text{CH}_2 - \text{CH}_2 - \text{N} \quad \text{N} - \text{CH}_3
\]

ftorpropazinum
ftorpropazine

10-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propionyl]-2-(trifluoromethyl)phenothiazine
C_{19}H_{19}F_{3}N_{2}O_{4}S

\[
\text{CO} - \text{CH}_2 - \text{CH}_2 - \text{N} - \text{CH}_2 - \text{CH}_2 \text{OH}
\]
<table>
<thead>
<tr>
<th>Proposed International Nonproprietary Name (Latin, English)</th>
<th>Chemical Name or Description, Molecular and Graphic Formulae</th>
</tr>
</thead>
<tbody>
<tr>
<td>gestadienol</td>
<td>17-hydroxy-19-norpregna-4,5-diene-3,20-dione $\text{C}<em>{20}\text{H}</em>{28}\text{O}_3$</td>
</tr>
<tr>
<td>gestadionol</td>
<td></td>
</tr>
<tr>
<td>glibornuridum</td>
<td>1-[(2-endo-hydroxy-3-endo-bornyl)-3-(p-tolylsulfonyl)urea] $\text{C}<em>{41}\text{H}</em>{38}\text{N}<em>{2}\text{O}</em>{6}\text{S}$</td>
</tr>
<tr>
<td>glibornuride</td>
<td></td>
</tr>
<tr>
<td>guamecyclum</td>
<td>$N\cdot[4\cdot(\text{amidinoamidino})\cdot1\cdot\text{piperazinylo}methyl\cdot]4\cdot(\text{dimethylamino})\cdot 1,4,4a,5,5a,6,8,8a\cdot\text{octahydro}-3,6,10,12,12a\cdot\text{pentahydroxy}-6\cdot\text{methyl\cdot} 1,11\cdot\text{dioxy}2\cdot\text{naphthacenecarboxamide}$ $\text{C}<em>{48}\text{H}</em>{44}\text{N}<em>{4}\text{O}</em>{14}$</td>
</tr>
<tr>
<td>guamecylidine</td>
<td></td>
</tr>
<tr>
<td>hepronicatum</td>
<td>2-ethyl-2-[(hydroxymethyl)-1,3-propanediol trinicotinate] $\text{C}<em>{26}\text{H}</em>{42}\text{N}_{2}$</td>
</tr>
<tr>
<td>hepronicate</td>
<td></td>
</tr>
<tr>
<td>Proposed International Nonproprietary Name (Latin, English)</td>
<td>Chemical Name or Description, Molecular and Graphic Formulae</td>
</tr>
<tr>
<td>-----------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>kallidinogenasum</td>
<td>an enzyme isolated from the pancreas or urine of mammals</td>
</tr>
<tr>
<td>kallidinogenase</td>
<td></td>
</tr>
<tr>
<td>ketoxulam</td>
<td>3-ethoxy-1,1-dihydroxy-2-butanone</td>
</tr>
<tr>
<td>ketoxal</td>
<td>C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;10&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt;</td>
</tr>
<tr>
<td></td>
<td>H&lt;sub&gt;2&lt;/sub&gt;C−CH−CO−CH(OH)&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td></td>
<td>OC&lt;sub&gt;2&lt;/sub&gt;H&lt;sub&gt;5&lt;/sub&gt;</td>
</tr>
<tr>
<td>laramycinum</td>
<td>an antibiotic obtained from cultures of <em>Streptomyces bikinis</em> var. <em>laranensis</em> or the same substance obtained by any other means</td>
</tr>
<tr>
<td>laramycin</td>
<td></td>
</tr>
<tr>
<td>loxapinum</td>
<td>2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[β,γ][1,4]oxazepine</td>
</tr>
<tr>
<td>loxapine</td>
<td>C&lt;sub&gt;23&lt;/sub&gt;H&lt;sub&gt;22&lt;/sub&gt;ClN&lt;sub&gt;2&lt;/sub&gt;O</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>mecrilatum</td>
<td>methyl 2-cyanoacrylate</td>
</tr>
<tr>
<td>mecrilate</td>
<td>C&lt;sub&gt;2&lt;/sub&gt;H&lt;sub&gt;5&lt;/sub&gt;NO&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td></td>
<td>H&lt;sub&gt;2&lt;/sub&gt;C−C−CO−O−CH&lt;sub&gt;3&lt;/sub&gt;</td>
</tr>
<tr>
<td>meglucyclinum</td>
<td>2-deoxy-2-[[4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene-carboxamido)methyl]amino]-β-D-glucopyranose</td>
</tr>
<tr>
<td>meglucycline</td>
<td>C&lt;sub&gt;19&lt;/sub&gt;H&lt;sub&gt;17&lt;/sub&gt;N&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;6&lt;/sub&gt;</td>
</tr>
<tr>
<td>Proposed International Nonproprietary Name (Latin, English)</td>
<td>Chemical Name or Description, Molecular and Graphic Formulae</td>
</tr>
<tr>
<td>-----------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>memotinum</td>
<td>3,4-dihydro-1-[(p-methoxyphenoxo)methyl]isoquinoline</td>
</tr>
<tr>
<td>memoline</td>
<td>C_{19}H_{17}NO_{3}</td>
</tr>
</tbody>
</table>
| | ![Chemical Structure](image)
| menitrazepamum | 5-(1-cyclohexen-1-yl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one |
| menitrazepam | C_{19}H_{17}N_{3}O_{3} |
| | ![Chemical Structure](image)
| mepiroxolum | 3-pyridinemethanol 1-oxide |
| mepiroxol | C_{7}H_{8}NO |
| | ![Chemical Structure](image)
<p>| metacetamolum | 3'-hydroxyacetanilide |
| metacetamol | C_{9}H_{9}NO_{2} |
| | <img src="image" alt="Chemical Structure" /> |</p>
<table>
<thead>
<tr>
<th>Proposed International Nonproprietary Name (Latin, English)</th>
<th>Chemical Name or Description, Molecular and Graphic Formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>metaplinum / metapine</td>
<td>2-methyl-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine</td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;21&lt;/sub&gt;H&lt;sub&gt;22&lt;/sub&gt;N&lt;sub&gt;3&lt;/sub&gt;S</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>meziplinum / mezipine</td>
<td>5,6-dihydro-5-[3-(methylamino)propyl]-11H-dibenz[b,e]azepine</td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;21&lt;/sub&gt;H&lt;sub&gt;21&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>miconazolum / miconazole</td>
<td>1-(2,4-dichlorophenoxy)propyl(2,4-dichlorobenzyl)oxyphenethylimidazole</td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;21&lt;/sub&gt;H&lt;sub&gt;15&lt;/sub&gt;ClN&lt;sub&gt;5&lt;/sub&gt;O</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>morantelum / morantel</td>
<td>trans-1,4,5,6-tetrahydro-1-methyl-2-[2-(3-methyl-2-thienyl)vinyl]-pyrimidine</td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;21&lt;/sub&gt;H&lt;sub&gt;18&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;S</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
<tr>
<td>Proposed International Nonproprietary Name (Latin, English)</td>
<td>Chemical Name or Description, Molecular and Graphic Formula</td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>nequinatun nequine</td>
<td>methyl 7-(benzylxoy)-5-buty1-1,4-dihydro-4-oxo-3-quinolinecarboxylate C_{18}H_{24}NO_{3}</td>
</tr>
<tr>
<td></td>
<td><img src="image1" alt="Molecular structure of nequine" /></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>nifenalol nifenalol</td>
<td>N-[[isopropylamino]methyl]-p-nitrobenzyl alcohol C_{14}H_{16}N_{2}O_{4}</td>
</tr>
<tr>
<td></td>
<td><img src="image2" alt="Molecular structure of nifenalol" /></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>nifurizynum nifurizone</td>
<td>1-{methylcarbamoyl}-3-[[3-(5-nitro-2-furyl)allylidene]amino]-2-imidazolidinone C_{16}H_{15}N_{3}O_{3}</td>
</tr>
<tr>
<td></td>
<td><img src="image3" alt="Molecular structure of nifurizone" /></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>nifurazolum nifurazole</td>
<td>3-(hydroxymethyl)-1-[[3-(5-nitro-2-furyl)allylidene]amino]hydantoin C_{16}H_{16}N_{3}O_{4}</td>
</tr>
<tr>
<td></td>
<td><img src="image4" alt="Molecular structure of nifurazole" /></td>
</tr>
<tr>
<td>Proposed International Nonproprietary Name (Latin, English)</td>
<td>Chemical Name or Description, Molecular and Graphic Formulae</td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>nitfurpirinolum nitfurpirinol</td>
<td>6-[2-(5-nitro-2-furyl)vinyl]-2-pyridinemethanol C_{6}H_{15}N_{3}O_{2}.</td>
</tr>
</tbody>
</table>

![Chemical Structure of nitfurpirinolum nitfurpirinol](image)

| nimorazolum nimorazole                                    | 4-[2-(5-nitroimidazol-4-yl)ethyl]morpholine C_{8}H_{19}N_{5}O_{2}. |

![Chemical Structure of nimorazolum nimorazole](image)

| nordiestebolum nordiestebol                               | 4-chloro-17β-hydroxyestr-4-en-3-one C_{21}H_{28}ClO_{5}. |

![Chemical Structure of nordiestebolum nordiestebol](image)

| ocriatatum ocrilate                                       | octyl 2-cyanoacrylate C_{8}H_{16}N_{3}O_{3}. |

![Chemical Structure of ocriatatum ocrilate](image)

| oxibetalatum oxibetaaine                                   | (carboxymethyl)dimehtyl(2-hydroxyethyl)ammonium hydroxide inner salt C_{4}H_{11}NO_{3}. |

![Chemical Structure of oxibetalatum oxibetaaine](image)
PENICYLCYCLINE

6-[2-[[4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido]-methyl]amino]-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

CₙHₙNₙOₙS

PEXANTEL

1-(cyclohexylcarbonyl)-4-methylpiperazine

CₙHₙNₙO

PICLOPASTINE

2-[8-[4-(p-chloro-2-pyridylbenzyl)-1-piperazinyl]ethoxy]ethanol

CₙHₙClNₙO₂

PIRACETAM

2-oxo-1-pyrrolidinoacetamide

CₙHₙNₙOₙ
pizotifenum
pizotifen

4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine
C₂₉H₂₃N₂S

podifenum
podifen

1-[α-methyl-3,4-(methylenedioxy)phenethyl]-4-(4-methyl-2-thiazolyl)-piperazine
C₂₃H₂₃N₃O₅S

poligeenanum
poligeenan

3,6-anhydro-4-O-β-D-galactopyranosyl-α-D-galactopyranose 2,4'-bis-(potassium/sodium sulfate) (1→3')-polysaccharide
(C₁₆H₂₄M₆O₈S₄)n

polietofum
polietef

poly(tetrafluoroethylene)
(C₂F₄)n
Prazosin

1-(4-amino-6,7-dimethoxy-2-quinazolyl)-4-(2-furoyl)piperazine

\[ \text{C}_2\text{H}_9\text{N}_2\text{O}_4 \]

Prednazoline

11β,17,21-trihydroxyprogna-1,4-diene-3,20-dione 21-(di-H phosphate) compound with 2-[[2-isopropylphenoxy)methyl]-2-imidazoline

\[ \text{C}_2\text{H}_9\text{N}_2\text{O}_4 \cdot \text{P} \cdot \text{C}_9\text{H}_8\text{N}_2\text{O} \]

Prospidium chloride

3,12-bis(3-chloro-2-hydroxypropyl)-3,12-diaza-6,9-diazoniadispro-[5,2.5,2]hexadecane dichloride

\[ \left[ \text{ClC}_2\text{H}_2\text{CH(OH)}\text{CH}_2\text{N} \begin{array}{c} \text{N} \end{array} \text{N} \text{CH}_2\text{CH(OH)}\text{CH}_2\text{Cl} \right]^{2+} \text{2Cl}^- \]

Ritodrine

\[ \text{p-hydroxy-\{1-[(p-hydroxyphenethyl)amino]ethyl\}benzyl alcohol} \]

\[ \text{C}_9\text{H}_9\text{NO}_3 \]

Rizolipase

Lipase of *Rhizopus arrhizus* var. *Delemar*
Proposed International Nonproprietary Name (Latin, English) | Chemical Name or Description, Molecular and Graphic Formulae
---|---
salazodinum | 5-[[p-(6-methoxy-3-pyridazinyl)sulfamoyl]phenyl]azo]salicylic acid 
| C14H16N2O5S

salazodine

simflibratum | 2-[(p-chlorophenoxy)-2-methylpropionic acid trimethylene ester 
| C28H25ClO4

simflibrate

sucralfatatum | sucrose hydrogen sulfate basic aluminum salt

sucralfate

temazepamum | 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 
| C19H16ClN2O2

temazepam
<table>
<thead>
<tr>
<th>Proprietary Name</th>
<th>Chemical Name or Description, Molecular and Graphic Formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>terbutaline</td>
<td>e-[(tert-butyramino)methyl]-3,5-dihydroxybenzyl alcohol C₂₁H₂₂NO₂</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="terbutaline structure" /></td>
</tr>
<tr>
<td>tibolone</td>
<td>17-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one C₂₇H₄₂O₅</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="tibolone structure" /></td>
</tr>
<tr>
<td>tiflimum</td>
<td>4-guanidinobutyramide C₇H₁₃N₂O</td>
</tr>
<tr>
<td>tiflurin</td>
<td><img src="image" alt="tiflurin structure" /></td>
</tr>
<tr>
<td>tipindolle</td>
<td>2-(dimethylamino)ethyl 1,3,4,5-tetrahydrothiopyrano[4,3-b]indole-8-carboxylate C₂₇H₂₇N₃O₅S</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="tipindolle structure" /></td>
</tr>
<tr>
<td>tramadol</td>
<td>(±)-trans-2-[[dimethylamino]methyl]-1-(m-methoxyphenyl)cyclohexanol C₂₀H₂₅NO₂</td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="tramadol structure" /></td>
</tr>
</tbody>
</table>
Proposed International Nonproprietary Name
(Latin, English)

trengestonum
tengestone

6-chlore-9β,10α-progna-1,4,6-triene-3,20-diene
C_{31}H_{41}ClO_{3}

trimebutinum
trimebutine

β-(dimethylamino)-β-ethylphenethyl alcohol 3,4,5-trimethoxybenzoate (ester)
C_{30}H_{38}NO_{5}

truxicurii iodium
truxicurium iodide
diethyl(3-hydroxypropyl)methylammonium iodide α-2,4-diphenyl-1,3-cyclobutanedicarboxylate
C_{39}H_{44}I_{2}N_{2}O_{8}

truxipicurii iodium
truxipicurium iodide
1-ethyl-1-(3-hydroxypropyl)piperidinium iodide α-2,4-diphenyl-1,3-cyclobutanedicarboxylate
C_{39}H_{45}I_{2}N_{2}O_{8}
vincaminum
vincamine

an alkaloid obtained from *Vinca minor*

\[
\begin{array}{c}
\text{H}_3\text{C} - \text{O} - \text{OC} \\
\text{C}_2\text{H}_5 \\
\end{array}
\]

xibornolum
xibornol

5-isobornyl-3,4-xylenol

\[
\begin{array}{c}
\text{CH}_3 \\
\text{CH}_3 \\
\text{CH}_3 \\
\text{CH}_3 \\
\end{array}
\]

xipamidum
xipamide

4-chloro-5-sulfamoyl-2',6'-salicyloxylidide

\[
\begin{array}{c}
\text{CO} - \text{NH} \\
\text{H}_2\text{N} - \text{SO}_2 \\
\end{array}
\]

xipranololum
xipranolol

1-(di-2,6-xylymethoxy)-3-(isopropyramino)-2-propanol

\[
\begin{array}{c}
\text{CH}_3 \\
\text{CH}_3 \\
\text{OH} \\
\end{array}
\]

\[
\begin{array}{c}
\text{H}_3\text{C} - \text{O} - \text{CH}_2 - \text{CH}_2 - \text{NH} - \text{CH}(\text{CH}_3)_2 \\
\text{H}_3\text{C} - \text{CH}_3 \\
\end{array}
\]
NAMES FOR RADICALS AND GROUPS

Some preparations for which a proposed international nonproprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. The following shorter nonproprietary names for some such radicals and groups have been devised or selected, and they are suggested for use with proposed international nonproprietary names.

\[ \text{N-acetylglycinate} \quad \text{H}_3\text{C} - \text{CO} - \text{NH} - \text{CH}_2 - \text{COO}^\ominus \quad \text{aceturate} \]

\[ \text{benzenesulfonate} \quad \text{SO}_3^\ominus \quad \text{besilate} \]

\[ \text{[(6-hydroxy-4-methyl-2-oxo-2H-1-benzopyran-7-yloxy)acetate} \quad \text{cromacate} \]

\[ \text{6,7-dihydroxycoumarin-4-methanesulfonate} \quad \text{cromesilate} \]

\[ \text{diethanolamine} \quad \text{HN} - \text{CH}_2 - \text{CH}_2 - \text{OH}_2 \quad \text{diolamine} \]

\[ \text{ethanolamine} \quad \text{H}_2\text{N} - \text{CH}_2 - \text{CH}_2 - \text{OH} \quad \text{olamine} \]

\[ \text{2-oxoglutarate} \quad \text{COO} - \text{CO} - \text{CH}_2 - \text{CH}_2 - \text{COOH} \quad \text{oxoglutarate} \]

\[ \text{tertiary butyl acetate} \quad \text{CH}_3 \quad \text{tebutate} \]

\[ \text{triethylamine} \quad \text{N} - \text{CH}_2 - \text{CH}_2 - \text{OH}_3 \quad \text{triolamine} \]
CORRIGENDA
Vol. 21, No. 11

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (Prop. I.N.N.): LIST 18

p. 480: delete
  benzozipinum
  benzazolinum

  insert
  metrizolinum
  metizoline

Vol. 22, No. 9

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (Prop. I.N.N.): LIST 20

p. 421: delete
  oprensinum
  opressin

  insert
  ornipressinum
  ornipressin

INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS
CUMULATIVE LIST No. 2, 1967

p. 10: delete
  alfasonum
  alfasonone

  insert
  algestonum
  algestone

p. 41: delete
  etomidatum
  etomidate

  insert
  (+)-ethyl 1-(a-methylbenzyl)imidazole-5-carboxylate
  (+)-ethyl 1-(a-methylbenzyl)imidazole-5-carboxylate
  C\textsubscript{31}H\textsubscript{24}N\textsubscript{2}O\textsubscript{3}

p. 41: delete
  etymidum
  etymide

  insert
  carbifenum
  carbifene

p. 45: delete
  gentamicum
  gentamicin

  insert
  gentamicinum
  gentamicin

p. 53: delete
  leucovorinum
  leucovorin

  insert
  calcii folinas
  calcium folinate

p. 56: delete
  melastatinum
  melastatine

  insert
  demelastinum
  demelastine

p. 68: delete
  nortestosteronum cypionas
  nortestosterone cypionate

  insert
  nandrolonum
  nandrolone

  17\textbeta\textendash\textit{Hydroxyestar}-4-en-3-one cyclopentanepropionate
  17\textbeta\textendash\textit{Hydroxyestar}-4-en-3-one
  C\textsubscript{29}H\textsubscript{34}O\textsubscript{3}
  C\textsubscript{29}H\textsubscript{34}O

p. 80: delete
  propoxyphenum
  propoxyphene

  4-dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate ester
  C\textsubscript{29}H\textsubscript{34}NO\textsubscript{3}

29
Annex

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES *

The following procedure shall be followed by the World Health Organization in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with the World Health Assembly resolution WHA31.11:

1. Proposals for recommended international nonproprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Nonproprietary Names", appended to this procedure. The name proposed by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international nonproprietary name is being considered.

   A. Such notice shall be given by publication in the Chronicle of the World Health Organization* and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

      (i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

   B. Such notice shall:

      (i) set forth the name under consideration;

      (ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;

      (iii) identify the substance for which a name is being considered;

      (iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;

      (v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the Chronicle of the World Health Organization.

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the Chronicle of the World Health Organization.

   A. Such objection shall:

      (i) identify the person objecting;

      (ii) state his interest in the name;

      (iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.


† The title of this publication was changed to WHO Chronicle in January 1959.
7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international nonproprietary name.

8. In forwarding a recommended international nonproprietary name to Member States under article 7, the Director-General of the World Health Organization shall:
   A. request that it be recognized as the nonproprietary name for the substance; and
   B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES

1. Names should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names already in common use.

2. The name for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic suggestion should be avoided.

The above primary principles are to be implemented by utilization of the following secondary principles.

3. In devising the name of the first substance in a new pharmacological group (the parent substance), consideration should be given to the possibility of devising suitable names for related substances belonging to the new group.

4. Syllables such as "methylhydro", "methoxy" and "chlor" should preferably be abbreviated to "methyl" "meto", "clo", etc.

5. In the naming of substances which are acids, existing names generally used in chemistry which include the word "acetic" ("-acetic") should be used, if the name is adequate for practical use in therapy and pharmacy. In other circumstances, the substance should be named by a single word and not by a name which includes the word "acid". Where the word "acid" is not used in the name, as is customary in the penicillin series, a salt should preferably be named without modification of the parent acid name, e.g., "oxacillin" and "oxacillin sodium".

6. Names for substances which are used as salts should in general apply to the active base (or the active acid). Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid (or the inactive base). Exceptions may have to be made for those cases in which pharmacological activity may reside in both parts of the salt or ester.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

7. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

8. To facilitate translation and pronunciation, "f" should preferably be used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y".

9. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

10. Group relationship in names (see item 2) should preferably be shown by using common syllables in the following list. Where a syllable or a group of syllables is shown without any hyphens it may be used anywhere in the name. The syllable, or group of syllables, should, if possible, be used only for such substances.

   Subsidiary group relationships should be shown by devising names which show similarities to and are analogous with a previously named substance, the parent substance.

   At the end of the list are general chemical syllables. Should they come into conflict with other suggested syllables, the suffix conveying the best information should be used.

* Text revised by the Expert Committee on Nonproprietary Names for Pharmaceutical Preparations (unpublished reports WHO/Pharm/67.445 and WHO/Pharm/68.447).
<table>
<thead>
<tr>
<th>Latin</th>
<th>English</th>
<th>French</th>
</tr>
</thead>
<tbody>
<tr>
<td>-andr-</td>
<td>-andr-</td>
<td>steroids, androgenic</td>
</tr>
<tr>
<td>or -stan-</td>
<td>or -stan-</td>
<td>polysulfonic anticoagulants</td>
</tr>
<tr>
<td>or -ster-</td>
<td>or -ster-</td>
<td>anticoagulants</td>
</tr>
<tr>
<td>-apoll</td>
<td>-apoll</td>
<td>tranquilizers of the propanediol and pentamethylen series</td>
</tr>
<tr>
<td>-arol</td>
<td>-arol</td>
<td>barbituric acids, hypnotic activity</td>
</tr>
<tr>
<td>-bamatum</td>
<td>-bamate</td>
<td>anabolic steroids</td>
</tr>
<tr>
<td>barb</td>
<td>barb</td>
<td>local anaesthetics</td>
</tr>
<tr>
<td>bol</td>
<td>bol</td>
<td>antibiotics with cephalosporanic acid nucleus</td>
</tr>
<tr>
<td>-calnin</td>
<td>-calne</td>
<td>penicillins: derivatives of carboxy-β-amino-penicillanic acid</td>
</tr>
<tr>
<td>cef-</td>
<td>cef-</td>
<td>steroids, glucocorticoids and mineralocorticoids, other than prednisolone derivatives</td>
</tr>
<tr>
<td>-cilinin</td>
<td>-ciline</td>
<td>acridine derivatives</td>
</tr>
<tr>
<td>-cort-</td>
<td>-cort-</td>
<td>curare-like drugs</td>
</tr>
<tr>
<td>-crinin</td>
<td>-crine</td>
<td>antibiotics, tetracycline derivatives</td>
</tr>
<tr>
<td>-curonium</td>
<td>-curonium</td>
<td>antiepileptics derived from oxazolidinedione</td>
</tr>
<tr>
<td>-cyclinin</td>
<td>-cycline</td>
<td>estrogenic drugs</td>
</tr>
<tr>
<td>-dionum</td>
<td>-dione</td>
<td>steroids, progestational</td>
</tr>
<tr>
<td>-estr-</td>
<td>-estr-</td>
<td>sulphonamide oral antidiabetics</td>
</tr>
<tr>
<td>-gest-</td>
<td>-gest-</td>
<td>iodine-containing contrast media</td>
</tr>
<tr>
<td>gli-</td>
<td>gli-</td>
<td>mercury-containing drugs, antimicrobial or diuretic</td>
</tr>
<tr>
<td>lo-</td>
<td>lo-</td>
<td>nucleotoxic, antineoplastic agents</td>
</tr>
<tr>
<td>-mer-</td>
<td>-mer-</td>
<td>mononamine, oxidase inhibitors</td>
</tr>
<tr>
<td>mito</td>
<td>mito</td>
<td>antimicrobial antibiotics, produced by Streptomyces strains</td>
</tr>
<tr>
<td>-maximum</td>
<td>-maxine</td>
<td>5-nitrofurren derivatives</td>
</tr>
<tr>
<td>-mycin</td>
<td>-mycine</td>
<td>anorexigenic agents</td>
</tr>
<tr>
<td>-nifur-</td>
<td>-nifur-</td>
<td>dibenzazepine, compounds of the imipramine type</td>
</tr>
<tr>
<td>-orexum</td>
<td>-orex-</td>
<td>quinoline derivatives</td>
</tr>
<tr>
<td>-praminum</td>
<td>-pramine</td>
<td>derivatives of Rauwolfia alkaloids</td>
</tr>
<tr>
<td>-quimun</td>
<td>-quime</td>
<td>anticholinesterases</td>
</tr>
<tr>
<td>-quinum</td>
<td>-quine</td>
<td>sulfonamides, used as antimicrobials</td>
</tr>
<tr>
<td>-serpinum</td>
<td>-serpine</td>
<td>diuretics which are thiazide derivatives</td>
</tr>
<tr>
<td>-stignimin</td>
<td>-stignime</td>
<td>antiepileptics which are hydantoin derivatives</td>
</tr>
<tr>
<td>sulf-</td>
<td>sulf-</td>
<td>spasmolytics with a papaverine-like action</td>
</tr>
<tr>
<td>-toinum</td>
<td>-toine</td>
<td>alkaloids and organic bases</td>
</tr>
<tr>
<td>-verinum</td>
<td>-verine</td>
<td>ketones</td>
</tr>
<tr>
<td>-inum</td>
<td>-ine</td>
<td>quaternary amines</td>
</tr>
<tr>
<td>-onum</td>
<td>-one</td>
<td></td>
</tr>
<tr>
<td>-ium</td>
<td>-ium</td>
<td></td>
</tr>
</tbody>
</table>